Updated Definition of Advanced Chronic Heart Failure
The 2007 and 2018 criteria of advanced chronic HF are outlined in Severe impairment of functional capacity shown by one of the following:
• inability to exercise; • 6MWTD < 300 m or less in women and/or patients aged ≥75 years; or • pVO 2 < 12-14 ml/kg/min 4. Severe impairment of exercise capacity with inability to exercise or low 6MWTD (<300 m) or pVO 2 (<12-14 ml/kg/min), estimated to be of cardiac origin
Presence of all features above despite attempts to optimise therapy including diuretics, inhibitors of the renin-angiotensin-aldosterone system, and beta-blockers, unless these are poorly tolerated or contraindicated, and cardiac resynchronisation therapy, when indicated.
In addition to the above, extracardiac organ dysfunction resulting from heart failure (e.g. cardiac cachexia, or liver or kidney dysfunction) or type 2 pulmonary hypertension may be present, but are not required. Criteria 1 and 4 can be met in patients who have cardiac dysfunction (as described in criterion 2), but also have substantial limitation caused by other conditions (e.g. severe pulmonary disease, non-cardiac cirrhosis or, most commonly, renal disease with mixed aetiology). These patients have a limited quality of life and survival because of advanced disease and warrant the same intensity of evaluation as someone in whom the only disease is cardiac; however, the therapeutic options for these patients are usually more limited. Advanced Chronic Heart Failure C A R D I A C FA I L U R E R E V I E W the use of multiparametric approaches likely better than one single measurement such as the E/e' ratio. 15, 16 Cardiopulmonary exercise testing (CPET) provides objective information about the exercise capacity of ambulatory patients with HF. It is indicated for the selection of candidates for heart transplantation.
6MWTD = 6-minute walk test distance; ARVC = arrhythmogenic right ventricular cardiomyopathy; BNP = B-type natriuretic peptide; EF = ejection fraction; ESC = European Society of
Peak exercise oxygen consumption (VO 2 ), measured both as per cent of maximal predicted values and as an absolute value, as well as minute ventilation/carbon dioxide production (VE/VCO 2 ) and an oscillatory pattern of ventilation during exercise have all been shown to have independent prognostic value. 17 Based on prognostic studies, heart transplantation is indicated when peak VO 2 is ≤14 ml/kg/min or ≤12 ml/kg/min in patients on beta-blockers. Achievement of a respiratory exchange rate >1.05 is important to define achievement of maximal aerobic capacity. Ventilatory response to exercise provides an objective assessment of exercise capacity, independently of patients' motivation and, along with the presence of an oscillatory pattern of ventilation, may further stratify the patients. 17 A low 6-minute walking test distance (6MWTD) may also be used in prognostic assessment.
Multivariable Prognostic Scores
Several multiparametric risk scores have been developed. They include the Heart Failure Survival Score (HFSS), the Seattle Heart Failure Model (SHFM), the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score and the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC).
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The HFSS was developed for the selection of candidates for heart transplantation among ambulatory patients with severe HF. Fully noninvasive models, including CPET, can be as accurate at predicting prognosis as those including invasive measurements. 19 The SHFM has been fully validated. It has shown an adequate discrimination power though underestimated the absolute risk in patients with advanced HF, namely in those indicated for MCS. 22 Its predictive value has also been shown in patients on MCS so it may be used to estimate outcomes compared with no intervention. 23 MAGGIC, which is based on individual data of 39,372 patients with heart failure with reduced ejection fraction and preserved ejection fraction from 30 cohort studies and six clinical trials, is among the most comprehensive and consistent. 18 The MECKI score includes CPET data, percent predicted pVO 2 and VE/VCO 2 slope, haemoglobin, serum sodium and renal function. It compares favourably with HFSS and SHFM, although the latter does not require CPET data. 24 A comparative study showed a similar predictive accuracy of the four scores with a tendency to underestimate event rates with the SHFM and HFSS scores and a tendency to overestimate them with MAGGIC and MECKI scores. 
